公开(公告)号：US20250145686A1

公开(公告)日：2025-05-08

申请号：US19012311

申请日：2025-01-07

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  A61K35/12 ,  A61K35/17 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K40/11 ,  A61K40/42 ,  C07K7/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6881 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250092104A1

公开(公告)日：2025-03-20

申请号：US18955513

申请日：2024-11-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Annika SONNTAG ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH ,  Colette SONG

IPC: C07K14/47 ,  A61K38/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240294602A1

公开(公告)日：2024-09-05

申请号：US18647837

申请日：2024-04-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A01N37/46 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/04 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20240239867A1

公开(公告)日：2024-07-18

申请号：US18433955

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  A61K38/00 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240218044A1

公开(公告)日：2024-07-04

申请号：US18421973

申请日：2024-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  A61K38/00 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240166714A1

公开(公告)日：2024-05-23

申请号：US18433913

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240166712A1

公开(公告)日：2024-05-23

申请号：US18433852

申请日：2024-02-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240117004A1

公开(公告)日：2024-04-11

申请号：US18544048

申请日：2023-12-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Lena WULLKOPF ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Daniel Johannes KOWALEWSKI ,  Michael ROEMER ,  Oliver SCHOOR

IPC: C07K14/725 ,  A61K35/17 ,  C07K14/74 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K35/17 ,  C07K14/70539 ,  C07K16/2833 ,  A61K38/00

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240100137A1

公开(公告)日：2024-03-28

申请号：US18533733

申请日：2023-12-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Andrea MAHR

IPC: A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886

CPC classification number: A61K39/0011 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70503 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0638 ,  C12N15/115 ,  C12Q1/6886 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/80 ,  C07K2317/32 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240075130A1

公开(公告)日：2024-03-07

申请号：US18505361

申请日：2023-11-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Frank SCHWOEBEL ,  Lena Katharina FREUDENMANN

IPC: A61K39/385 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  A61P11/00 ,  A61P35/04 ,  A61P37/04 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/574

CPC classification number: A61K39/385 ,  A61K35/17 ,  A61K38/1774 ,  A61K38/20 ,  A61K38/2046 ,  A61K38/2086 ,  A61P11/00 ,  A61P35/04 ,  A61P37/04 ,  C07K14/7051 ,  C07K16/2809 ,  C12N5/0638 ,  C12N5/10 ,  G01N33/57492 ,  A61K2039/53

Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).